Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
37.46
+0.60 (1.63%)
Feb 21, 2025, 4:00 PM EST - Market closed
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Crinetics Pharmaceuticals stock have an average target of 72.64, with a low estimate of 54 and a high estimate of 97. The average target predicts an increase of 93.91% from the current stock price of 37.46.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2025.
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 8 | 8 | 7 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 10 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Feb 4, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $55 | Hold → Strong Buy | Upgrades | $55 | +46.82% | Jan 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $81 | Strong Buy | Reiterates | $81 | +116.23% | Jan 13, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $87 | Buy | Reiterates | $87 | +132.25% | Dec 16, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $70 → $74 | Strong Buy | Maintains | $70 → $74 | +97.54% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
1.68M
from 4.01M
Decreased by -58.14%
Revenue Next Year
5.14M
from 1.68M
Increased by 206.01%
EPS This Year
-3.77
from -3.69
EPS Next Year
-3.94
from -3.77
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 6.3M | 10.5M | 65.1M | |||
| Avg | 1.7M | 5.1M | 41.4M | |||
| Low | 980,000 | 2.6M | 27.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 57.0% | 525.0% | 1,166.3% | |||
| Avg | -58.1% | 206.0% | 704.9% | |||
| Low | -75.6% | 57.5% | 426.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -3.68 | -2.57 | -2.56 | |||
| Avg | -3.77 | -3.94 | -4.38 | |||
| Low | -3.90 | -5.29 | -5.92 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.